## Endometrium Cancer Histopathology Reporting Proforma

Mandatory questions (i.e. protocol standards) are in bold (e.g. **S1.01**).

### S1.01 Identification

<table>
<thead>
<tr>
<th>Family name</th>
<th>Sex</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Given name(s)</th>
<th>Ethnicity</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Date of birth</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>DD – MM – YYYY</td>
<td></td>
</tr>
</tbody>
</table>

**Patient identifiers**

- e.g. MRN, IHI or NHI (please indicate which)

**Date of request**

**S1.02 Accession number**

<table>
<thead>
<tr>
<th>DD – MM – YYYY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

**Requesting doctor - name and contact details**

### Clinical details

#### S1.03 Principal clinician

#### S1.04 Operative procedure/ specimen

- Total hysterectomy
- Subtotal hysterectomy
- Radical hysterectomy

**Accompanying specimens**

#### S1.05 Metastatic disease?

- Not stated
- Absent (on both clinical & operative grounds)
- Present
  - Pre-operative
  - Intra-operative

**Details of any previous or current treatment of the present tumour**

**Details of any other prior cancer diagnosis**

**Details of any family history of cancer**
### Macroscopic findings

#### S2.04 Lymph nodes

| SITE 1 | | SITE 3 | | SITE 4 | | SITE 5 | | SITE 6 |
|---|---|---|---|---|---|---|---|
| Description | Total number of nodes | Max. diameter/ size range | mm to mm | | Description | Total number of nodes | Max. diameter/ size range | mm to mm | | Description | Total number of nodes | Max. diameter/ size range | mm to mm | | Description | Total number of nodes | Max. diameter/ size range | mm to mm |
**SITE 7**

Description

Total number of nodes

Max. diameter/ size range

**S2.05 Omentum**

Dimensions

\[ \text{length mm} \times \text{width mm} \times \text{thickness mm} \]

Proportion of fat replaced by tumour

% est.

Description

**SITE 1**

Dimensions

\[ \text{length mm} \times \text{width mm} \times \text{thickness mm} \]

Description

**SITE 2**

Dimensions

\[ \text{length mm} \times \text{width mm} \times \text{thickness mm} \]

Description

**SITE 3**

Dimensions

\[ \text{length mm} \times \text{width mm} \times \text{thickness mm} \]

Description

**S2.07 Ovaries**

**Left Ovary**

Surface

Dimensions

\[ \text{length mm} \times \text{width mm} \times \text{thickness mm} \]

Description

**Right Ovary**

Surface

Dimensions

\[ \text{length mm} \times \text{width mm} \times \text{thickness mm} \]

Description

**S2.08 Fallopian tubes**

**Left fallopian tube**

Dimensions

\[ \text{Length x max. diameter} \]

\[ \text{length mm} \times \text{diameter mm} \]

Description

**Right fallopian tube**

Dimensions

\[ \text{Length x max. diameter} \]

\[ \text{length mm} \times \text{diameter mm} \]
Right fallopian tube

Description

S2.09 External appearance of uterus
Uterus received:
- Intact
- Opened
Serosal surface:

S2.10 Weight of uterus


S2.11 Measurements of uterus
Midline fundal-serosa to ectocervix


Max. intercornual


Max. anterior to posterior


Gross description

S2.12 Site of tumour:
- Anterior endometrium
- Posterior endometrium
- Fundal endometrium
- Cornual recess
- Isthmus

Tumour dimensions
(superior-inferior x transverse x thickness where thickness = exophytic + endophytic)


G2.05 Distance of endometrial tumour from the inferior surgical margin on gross exam


S2.13 Paraffin block identification key


S2.14 Gross depth of maximal myometrial invasion


Thickness of normal (uninvolved) myometrial wall


S2.15 Cervical tissues
Description

If tumour present, record...

Dimensions


Microscopic findings

**S3.01  Lymph node involvement by tumour**

**SITE 1**

Number of nodes involved by tumour

Total number of nodes resected

Max. dimension of the metastasis or size range

Extranodal spread

**SITE 2**

Number of nodes involved by tumour

Total number of nodes resected

Max. dimension of the metastasis or size range

Extranodal spread

**SITE 3**

Number of nodes involved by tumour

Max. dimension of the metastasis or size range

Extranodal spread

**SITE 4**

Number of nodes involved by tumour

Total number of nodes resected

Max. dimension of the metastasis or size range

Extranodal spread

**SITE 5**

Number of nodes involved by tumour

Total number of nodes resected

Max. dimension of the metastasis or size range

Extranodal spread

**SITE 6**

Number of nodes involved by tumour

Distance of cervical tumour from the inferior surgical margin

Max. depth of cervical wall invasion

Thickness of normal (uninvolved) cervical wall

G2.06  Other relevant macroscopic comment
<table>
<thead>
<tr>
<th>Site 6 Continued</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total number of nodes resected</strong></td>
</tr>
<tr>
<td><strong>Max. dimension of the metastasis or size range</strong></td>
</tr>
<tr>
<td>mm to mm</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Extranodal spread</th>
</tr>
</thead>
<tbody>
<tr>
<td>Absent [ ]</td>
</tr>
<tr>
<td>Present [ ]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Site 7</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Number of nodes involved by tumour</strong></td>
</tr>
<tr>
<td><strong>Total number of nodes resected</strong></td>
</tr>
<tr>
<td><strong>Max. dimension of the metastasis or size range</strong></td>
</tr>
<tr>
<td>mm to mm</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Extranodal spread</th>
</tr>
</thead>
<tbody>
<tr>
<td>Absent [ ]</td>
</tr>
<tr>
<td>Present [ ]</td>
</tr>
</tbody>
</table>

### S3.02 Omental involvement:
- Tumour free [ ]
- Involved [ ]

**Nature of involvement:**

### S3.03 Peritoneal involvement:
- Tumour free [ ]
- Involved [ ]

**Nature of involvement:**

### S3.04 Ovarian involvement:
- Tumour free [ ]
- Involved [ ]

**Nature of involvement:**

### S3.05 Fallopian tubal involvement:
- Tumour free [ ]
- Involved [ ]

**Nature of involvement:**

### S3.06 Histological tumour type:
- Endometrioid adenocarcinoma [ ]
- and variant [ ]
- Mucinous adenocarcinoma [ ]
- Serous carcinoma [ ]
- Clear cell carcinoma [ ]
- Carcinosarcoma [ ]
- Undifferentiated carcinoma [ ]
- Other Tumour Type [ ]

**Mixed types of endometrial carcinomas:**

(STATE ALL AND RELATIVE PERCENTAGES)

and

and

### S3.07 Histological grade for endometrioid carcinomas:
- FIGO [ ]
  - Grade 1 [ ]
  - Grade 2 [ ]
  - Grade 3 [ ]
  - Grading not applicable [ ]
- Other grading system [ ]

### S3.08 Maximum microscopic depth of myometrial invasion

**mm**

(in histologic slide No:______)

**Normal myometrial wall thickness**

**mm**
S3.09 **Lymphovascular invasion**

- Absent □
- Present □

  - At the tumour interface □
  - Remote to the tumour interface ▼
  - Max. distance from tumour face

S3.10 **Cervical involvement:**

**Involvement of cervical mucosa only**

- Absent □
- Present & in-continuity □
- Present & separate □

**Involvement of cervical stroma**

- Absent □
- Present □ in-continuity □ separate □

  - Maximum invasive depth
    - mm

  - Normal cervical wall thickness
    - mm

**Cervical vascular involvement**

- Absent □
- Present □

S3.11 **Residual non-tumourous endometrium**

- Atrophic/cycle phase □
- Hyperplastic □
- Atypical hyperplastic □

**Description (eg polyps)**

In situ carcinoma:

- Absent □
- Present □

Multicentric/multifocal carcinoma:

- Absent □
- Present □

**Histological type**

**Extent**

**Sites**

G3.03 Other relevant microscopic comment

G4.01 **Histochemical stains**

G4.02 **Immunohistochemical stains**

<table>
<thead>
<tr>
<th>Positive Abs</th>
<th>Negative Abs</th>
<th>Equivocal Abs</th>
</tr>
</thead>
</table>

  - Interpretation
  - Clinical significance

**Synthesis and overview**

S5.01 **Tumour stage FIGO** (see p8)

Pathological tumour stage (pTNM)**

- T □
- N □
- M □

S5.02 **Year of publication and edition of cancer staging system**

G5.01 **Residual tumour status**

- RX □
- R0 □
- R1 □
- R2 □

G5.02 **Diagnostic summary**

Include: operative procedure/specimen type; tumour type and stage; residual tumour status
## Tumour stage FIGO & pTNM**

<table>
<thead>
<tr>
<th>Primary Tumour (T) (Surgical-Pathologic Findings)</th>
<th>FIGO</th>
</tr>
</thead>
<tbody>
<tr>
<td>TX</td>
<td>TX</td>
</tr>
<tr>
<td>T0</td>
<td>No evidence of primary tumour</td>
</tr>
<tr>
<td>Tis*</td>
<td>Carcinoma in situ (preinvasive carcinoma)</td>
</tr>
<tr>
<td>T1 I</td>
<td>Tumour confined to corpus uteri</td>
</tr>
<tr>
<td>T1a IA</td>
<td>Tumour limited to endometrium or invades less than one-half of the myometrium</td>
</tr>
<tr>
<td>T1b IB</td>
<td>Tumour invades one-half or more of the myometrium</td>
</tr>
<tr>
<td>T2 II</td>
<td>Tumour invades stromal connective tissue of the cervix but does not extend beyond uterus**</td>
</tr>
<tr>
<td>T3a IIIA</td>
<td>Tumour involves serosa and/or adnexa (direct extension or metastasis)</td>
</tr>
<tr>
<td>T3b IIIB</td>
<td>Vaginal involvement (direct extension or metastasis) or parametrial involvement.</td>
</tr>
<tr>
<td>T4 IVA</td>
<td>Tumour invades bladder mucosa and/or bowel mucosa (bullous oedema is not sufficient to classify a tumour as T4)</td>
</tr>
</tbody>
</table>

### Regional Lymph Nodes (N)

| N0                                           | No regional lymph node metastasis |
| N1 IIIIC1                                     | Regional lymph nodes metastasis to pelvic lymph nodes |
| N2 IIIIC2                                     | Regional lymph nodes metastasis to para-aortic lymph nodes, with or without positive pelvic lymph nodes. |

### Distant Metastasis (M)

| M0                                           | No distant metastasis |
| M1 IVB                                        | Distant metastasis (includes metastasis to inguinal lymph nodes intraperitoneal disease, or lung, liver, or bone. It excludes metastasis to para-aortic lymph nodes, vagina, pelvic serosa, or adnexa. |

* Note: FIGO no longer includes Stage 0(Tis)

** Endocervical glandular involvement only should be considered Stage I and not as Stage II.